share_log

Morgan Stanley Maintains Equal-Weight on Foghorn Therapeutics, Lowers Price Target to $6

Benzinga ·  Nov 13, 2023 09:08

Morgan Stanley analyst Vikram Purohit maintains Foghorn Therapeutics (NASDAQ:FHTX) with a Equal-Weight and lowers the price target from $10 to $6.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment